Published in J Clin Oncol on April 15, 2001
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 2.91
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol (2009) 2.02
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70
Patterns and correlates of local therapy for women with ductal carcinoma-in-situ. J Clin Oncol (2005) 1.53
The diagnosis and management of pre-invasive breast disease: flat epithelial atypia--classification, pathologic features and clinical significance. Breast Cancer Res (2003) 1.41
Breast cancer guidelines for Uganda (2nd Edition 2008). Afr Health Sci (2008) 1.23
A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer (2010) 1.18
A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat (2015) 1.12
"Well, have I got cancer or haven't I?" The psycho-social issues for women diagnosed with ductal carcinoma in situ. Health Expect (2002) 1.06
Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study. Cancer (2008) 1.03
Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast Cancer Res (2006) 1.02
Columnar cell lesions and subsequent breast cancer risk: a nested case-control study. Breast Cancer Res (2010) 1.01
[Prognostic factors in ductal carcinoma in situ]. Pathologe (2006) 1.00
A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Res Treat (2010) 1.00
Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Br J Cancer (2002) 0.99
The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.99
The impact of adding radiation treatment after breast conservation surgery for ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 0.99
The diagnosis and management of pre-invasive breast disease: pathological diagnosis--problems with existing classifications. Breast Cancer Res (2003) 0.98
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res (2009) 0.97
Flat DIN 1 (flat epithelial atypia) on core needle biopsy: 63 cases identified retrospectively among 1,751 core biopsies performed over an 8-year period (1992-1999). Virchows Arch (2007) 0.96
Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer (2009) 0.93
Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.93
Non-operative breast pathology: columnar cell lesions. J Clin Pathol (2006) 0.92
The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer (2012) 0.91
Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat (2013) 0.90
Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol (2015) 0.90
Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther (2010) 0.89
Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. J Surg Oncol (2009) 0.87
Tumor intrinsic subtype is reflected in cancer-adjacent tissue. Cancer Epidemiol Biomarkers Prev (2014) 0.86
Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ: Analysis of 2996 Women Treated With Breast-conserving Surgery for 30 Years. Ann Surg (2015) 0.85
Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer (2012) 0.85
Flat epithelial atypia with and without atypical ductal hyperplasia: to re-excise or not. Results of a 5-year prospective study. Virchows Arch (2012) 0.85
Ductal carcinoma in situ: recent advances and future prospects. Int J Surg Oncol (2012) 0.84
Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective. J Natl Cancer Inst Monogr (2010) 0.84
Flat epithelial atypia and risk of breast cancer: A Mayo cohort study. Cancer (2015) 0.84
Web based pathology assessment in RTOG 98-04. J Clin Pathol (2014) 0.84
Radiotherapy after conservative surgery in ductal carcinoma in situ of the breast: a review. Int J Surg Oncol (2012) 0.84
Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. Breast Cancer Res (2015) 0.84
Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol (2009) 0.82
Biological Markers Predictive of Invasive Recurrence in DCIS. Clin Med Oncol (2008) 0.82
Expression analysis of carbohydrate antigens in ductal carcinoma in situ of the breast by lectin histochemistry. BMC Cancer (2008) 0.82
A review of current practices in breast conservation surgery in the UK. Ann R Coll Surg Engl (2007) 0.82
Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? Virchows Arch (2008) 0.82
Local control of ductal carcinoma in situ based on tumor and patient characteristics: the surgeon's perspective. J Natl Cancer Inst Monogr (2010) 0.81
An adequate margin of excision in ductal carcinoma in situ. BMJ (2005) 0.80
Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast. Br J Cancer (2004) 0.80
Safe negative margin width in breast conservative therapy: results from a population with a high percentage of negative prognostic factors. World J Surg (2014) 0.80
Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis. Eur J Cancer Prev (2016) 0.79
Progression of Ductal Carcinoma in Situ from the Pathological Perspective. Breast Care (Basel) (2010) 0.79
[Flat epithelial neoplasia and other columnar cell lesions of the breast]. Pathologe (2006) 0.79
Accelerated partial breast irradiation with brachytherapy: patient selection and technique considerations. Breast Cancer (Dove Med Press) (2015) 0.78
Variability in the quality of pathology reporting of margin status following breast cancer surgery. Ann Surg Oncol (2011) 0.78
New biomarkers to predict the evolution of in situ breast cancers. Biomed Res Int (2014) 0.78
Breast cancer (non-metastatic). BMJ Clin Evid (2011) 0.77
Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review. Int J Surg Oncol (2012) 0.77
Lattice-based model of ductal carcinoma in situ suggests rules for breast cancer progression to an invasive state. PLoS Comput Biol (2014) 0.77
Breast cancer (non-metastatic). BMJ Clin Evid (2007) 0.75
Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat (2016) 0.75
Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Ann Surg Oncol (2016) 0.75
Close or positive resection margins are not associated with an increased risk of chest wall recurrence in women with DCIS treated by mastectomy: a population-based analysis. Springerplus (2015) 0.75
Development and testing of a single frequency terahertz imaging system for breast cancer detection. IEEE J Biomed Health Inform (2013) 0.75
Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol (2014) 0.75
Role of the radiotherapy boost on local control in ductal carcinoma in situ. Int J Surg Oncol (2012) 0.75
[Flat epithelial atypia]. Pathologe (2009) 0.75
The diagnostic challenge of low-grade ductal carcinoma in situ. Eur J Cancer (2017) 0.75
Eosinophilic inflammation in asthma. N Engl J Med (1990) 8.05
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol (2001) 5.28
Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst (2000) 4.15
Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet (1991) 4.09
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Stress and relapse of breast cancer. BMJ (1989) 3.07
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (1994) 2.92
The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer (1999) 2.89
Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet (2000) 2.87
Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature (1995) 2.83
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer (1992) 2.67
[The treatment of ductal carcinoma in situ (DCIS) of the breast]. Ned Tijdschr Geneeskd (2003) 2.67
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst (2000) 2.56
Familial breast cancer. BMJ (1994) 2.54
Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature (1997) 2.44
Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell (1993) 2.42
Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer (2003) 2.40
[Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer"]. Ned Tijdschr Geneeskd (2002) 2.39
Multiple phosphorylation sites in mammalian neurofilament polypeptides. J Biol Chem (1982) 2.34
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Who needs steroid receptor assays? Lancet (1989) 2.27
Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg (1989) 2.23
Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res (1997) 2.22
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol (2001) 2.21
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp Neurol (1997) 2.11
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene (2010) 2.11
The structure of a human neurofilament gene (NF-L): a unique exon-intron organization in the intermediate filament gene family. Biochim Biophys Acta (1987) 2.10
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
Metastases to the breast: differential diagnosis from primary breast carcinoma. J Surg Oncol (1991) 2.02
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer (2013) 2.01
Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer (1987) 1.97
Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res (1995) 1.96
Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol (1993) 1.91
Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr (1992) 1.89
Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology (2003) 1.89
Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation. Lancet (1990) 1.86
The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol (1988) 1.83
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol (1994) 1.80
A controlled trial of short-term versus standard axillary drainage after axillary clearance and iridium implant treatment of early breast cancer. Ann R Coll Surg Engl (1991) 1.72
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron (2001) 1.68
The distribution of phosphorylation sites among identified proteolytic fragments of mammalian neurofilaments. J Biol Chem (1983) 1.68
Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol (2003) 1.66
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
An improved CAT assay for promoter analysis in either transgenic mice or tissue culture cells. DNA Cell Biol (1992) 1.59
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene (2009) 1.58
Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer (2004) 1.58
Integrators of the cytoskeleton that stabilize microtubules. Cell (1999) 1.56
Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST) Eur J Cancer (1999) 1.55
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Male breast cancer. Int J Clin Pract (2000) 1.51
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys (1998) 1.49
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood (1994) 1.48
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer (1999) 1.46
The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat (1995) 1.46
Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) 1.45
Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol (2001) 1.44
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol (2009) 1.44
p53 mutations occur in aggressive breast cancer. Cancer Res (1992) 1.43
[Diagnostics in clinically occult, radiologically suspect breast lesions more often surgery than needle diagnostics with image monitoring]. Ned Tijdschr Geneeskd (2001) 1.43
Surgical correction of gynaecomastia in bodybuilders. Br J Clin Pract (1995) 1.43
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer (2004) 1.42
Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol (1996) 1.42
Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet (1994) 1.42
[Identification of the sentinel node in patients with breast carcinoma]. Ned Tijdschr Geneeskd (1996) 1.42
Follow-up of patients with aspirated breast cysts is necessary. Arch Surg (1989) 1.41
The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol (1999) 1.40
[Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer]. Ned Tijdschr Geneeskd (2004) 1.40
Additional copies of 1q in sequential samples from a phyllodes tumor of the breast. Cancer Genet Cytogenet (1995) 1.40
Pooling sera to reduce the cost of HIV surveillance: a feasibility study in a rural Kenyan district. Trop Med Int Health (1998) 1.40
A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer (2005) 1.40
Adult onset Still's disease and pregnancy. J Rheumatol (1993) 1.39
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer (1996) 1.39